Cancer, Lipids, and Metabolism

New review finds thyroid cancer drugs linked with longer survival in advanced disease

A systematic review and meta-analysis of randomized trials in people with advanced thyroid carcinoma examined tyrosine kinase inhibitors, a group of targeted cancer medicines. Across 13 trials involving 2,671 people, these medicines were associated with longer progression-free survival and overall survival than placebo, although the studies differed considerably in their progression-free survival results. The findings apply to advanced thyroid carcinoma studied in clinical trials, not to all thyroid cancers or all patients.